#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

Smoking cessation, moderate drinking, a healthy diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer.

Successful treatment with direct-acting antivirals prolonged survival by 18 months.

People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

People with liver cirrhosis often have substantial financial burden that interferes with their care.

October is Liver Cancer Awareness Month.

Those diagnosed with liver cancer after an HCV cure had a 66% lower risk of death.

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

Karen Hoyt promised her grandkids she would win a gold medal in the World Transplant Games. She wasn’t going to let HCC stand in her way.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.

Study in China sees an association with several cancer types, especially gastrointestinal malignancies.

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

There are now five targeted therapies for the most common type of liver cancer.

Do you know your liver cancer risk?

Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.